A Single Patient Protocol for TNB-383B, a Bispecific Antibody Targeting BCMA in a Subject With Relapsed/Refractory Multiple Myeloma
Latest Information Update: 05 Dec 2021
At a glance
- Drugs TNB 383B (Primary)
- Indications Multiple myeloma
- Focus Expanded access; Therapeutic Use
- Sponsors TeneoBio
Most Recent Events
- 10 Jul 2020 Status changed from recruiting to completed.
- 02 Jul 2020 New trial record